SCHEMBL24570907

SCHEMBL24570907

N#CC1CCNCC12CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24819506 0.74
SCHEMBL19815886 0.74
SCHEMBL19815889 0.74
Hydrochloric Acid SCHEMBL30037141 0.72
SCHEMBL31460294 0.71 CYP1A2 (0.31)
SCHEMBL25320023 0.70
SCHEMBL31124912 0.67
SCHEMBL24139829 0.65
SCHEMBL2898699 0.65
SCHEMBL9900272 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624003-B2 Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases CELGENE CORPORATION (US) 2026-05-12 US disclosed
EP-4267117-B1 CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORP (US) 2026-04-08 EP disclosed
US-20240124394-A1 Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases CELGENE CORPORATION (US) 2024-04-18 US disclosed
EP-4267117-A1 CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2023-11-01 EP disclosed
CN-116685313-A Indanyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases 细胞基因公司 2023-09-01 CN disclosed
WO-2022140555-A1 CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2022-06-30 WO disclosed
WO-2022140555-A1 CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2022-06-30 WO disclosed